Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 545Lymphoma 444Precursor Cell Lymphoblastic Leukemia-Lymphoma 409Lymphoma, Large B-Cell, Diffuse 347Leukemia 344Multiple Myeloma 335Lymphoma, Non-Hodgkin 316Leukemia, Myeloid, Acute 288Leukemia, Lymphocytic, Chronic, B-Cell 285Lymphoma, Follicular 240Burkitt Lymphoma 217Myelodysplastic Syndromes 209Lymphoma, Mantle-Cell 201Hodgkin Disease 193Recurrence 153Lymphoma, B-Cell, Marginal Zone 142Melanoma 135Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 96Triple Negative Breast Neoplasms 93Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mesothelin-positive Advanced Refractory Solid Tumors × Cyclophosphamide × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡